Previous 10 | Next 10 |
Intercept Pharma (NASDAQ:ICPT): Q3 GAAP EPS of -$0.11 beats by $0.98. Revenue of $92.87M (+16.8% Y/Y) beats by $9.83M. Press Release Company increases 2021 guidance of Ocaliva net sales to $355 million to $370 million and narrows Non-GAAP adjusted operating expense gu...
Worldwide Ocaliva® net sales of $92.8 million, representing 17% growth over the prior year quarter Company increases 2021 guidance of Ocaliva net sales to $355 million to $370 million and narrows Non-GAAP adjusted operating expense guidance to $380 ...
Intercept Pharma (NASDAQ:ICPT) is scheduled to announce Q3 earnings results on Wednesday, November 3rd, before market open. The consensus EPS Estimate is -$1.09 and the consensus Revenue Estimate is $83.04M (+4.4% Y/Y). Intercept shares rose more than 3% in reaction to posting ...
Late-breaking oral presentation compares transplant-free survival in patients with PBC treated with OCA to external controls from the Global PBC and UK-PBC study groups Poster presentations describe a new consensus panel biopsy reading methodology for NASH clinical trials and th...
NEW YORK, Oct. 27, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will announce its third quarter 2021 financial re...
The race is on to get a commercial biotech treatment asset targeting Nonalcoholic steatohepatitis, or “NASH”. NASH is sadly one of the fastest growing treatable major health problems on the planet right now, and analysts believe the resulting commercial opportunity could be as b...
The Covid story is starting to change. And you can hear the popping sound in the vaccine space. The needle is “therapeutics”. The therapeutic route was thought to be tricky for this virus on the near-term time horizon, which fueled a massive tsunami into the vaccine stocks as la...
Palm Beach, FL –October 12, 2021 – FinancialNewsMedia.com News Commentary – Atopic Dermatitis is an inflammatory skin disease, and the degree of its severity varies from patient to patient. It usually begins in childhood and is mostly confined to the flexura...
The following slide deck was published by Intercept Pharmaceuticals, Inc. in conjunction with this event. For further details see: Intercept Pharmaceuticals (ICPT) Presents at Global Healthcare Virtual Conference - Slideshow
InvestorPlace - Stock Market News, Stock Advice & Trading Tips For most lay participants in the markets, the equities sector represents a one-way street. Banking on the upward bias of U.S.-based blue chips, almost every financial advisor recommends a buy-and-hold strategy for those who...
News, Short Squeeze, Breakout and More Instantly...
Intercept Pharmaceuticals Inc. Company Name:
ICPT Stock Symbol:
NASDAQ Market:
Intercept Pharmaceuticals Inc. Website:
MORRISTOWN, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc., a biopharmaceutical company and wholly owned subsidiary of Alfasigma S.p.A. focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, today announced five abs...
sNDA intended to satisfy post-marketing requirements to confirm a clinical benefit in patients with PBC Precedent-setting submission includes data from post-marketing studies COBALT and Study 401 as well as real-world evidence from a claims database and patient registries FDA has assign...
Data from two Phase 2 studies in PBC show combination of OCA + bezafibrate achieved biochemical remission (normalization of ALP, total bilirubin, GGT, ALT and AST) in 40-44% of patients in the first 12 weeks OCA 5 or 5-10 mg + bezafibrate 400 mg cohorts in both studies showed a >60% ...